Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guided Therapeutics - GTHP -- Ignore unavailable to you. Want to Upgrade?

To: Robin who wrote (10)	4/10/1998 10:21:00 PM
From: CatLady	Read Replies (1) \| Respond to of 118

Thanks for the writeup. SPRX's partnership agreements look very good! Gives them a high degree of credibility, IMHO. I'm trying to find out where they stand with the FDA filing process, are you aware of the status? CL

To: Robin who wrote (10)	5/14/1998 11:23:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 118

I tested both Bilicheck on myself and friends, and CCSI (Colormate?) at the New Orleans meeting of the Pediatric Research Societies (May 1 to 5) and did not find any major difference between them in terms of technology or ease of use. The Bilicheck has a small extra piece for control (and it costs some additional money). Both will sell in the $3,000 range. Patient bill expenses will be covered by insurance companies for both (very important). There were several poster presentations about the use of both instruments with good results in newborn babies. Respironics booth was also promoting Bilicheck at the meeting in New Orleans.